These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 19228072)
41. Are Seretide and Symbicort useful in COPD? Drug Ther Bull; 2004 Mar; 42(3):18-21. PubMed ID: 15038079 [TBL] [Abstract][Full Text] [Related]
42. Symbicort® Maintenance and Reliever Therapy (SMART) and the evolution of asthma management within the GINA guidelines. Lin J; Zhou X; Wang C; Liu C; Cai S; Huang M Expert Rev Respir Med; 2018 Mar; 12(3):191-202. PubMed ID: 29400090 [TBL] [Abstract][Full Text] [Related]
43. Use of long-acting beta-agonists and inhaled steroids in asthma: meta-analysis of observational studies. Hirst C; Calingaert B; Stanford R; Castellsague J J Asthma; 2010 May; 47(4):439-46. PubMed ID: 20528600 [TBL] [Abstract][Full Text] [Related]
44. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. FitzGerald JM; Boulet LP; Follows RM Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813 [TBL] [Abstract][Full Text] [Related]
45. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler. Berger WE; Noonan MJ J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601 [TBL] [Abstract][Full Text] [Related]
46. Overall asthma control: the relationship between current control and future risk. Bateman ED; Reddel HK; Eriksson G; Peterson S; Ostlund O; Sears MR; Jenkins C; Humbert M; Buhl R; Harrison TW; Quirce S; O'Byrne PM J Allergy Clin Immunol; 2010 Mar; 125(3):600-8, 608.e1-608.e6. PubMed ID: 20153029 [TBL] [Abstract][Full Text] [Related]
47. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. FitzGerald JM; Sears MR; Boulet LP; Becker AB; McIvor AR; Ernst P; Smiljanic-Georgijev NM; Lee JS; Can Respir J; 2003; 10(8):427-34. PubMed ID: 14679407 [TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma. Doull I; Price D; Thomas M; Hawkins N; Stamuli E; Tabberer M; Gosden T; Rudge H Curr Med Res Opin; 2007 May; 23(5):1147-59. PubMed ID: 17519082 [TBL] [Abstract][Full Text] [Related]
49. Inhaled steroid/long-acting beta 2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients. Lötvall J; Langley S; Woodcock A Respir Res; 2006 Aug; 7(1):110. PubMed ID: 16919161 [TBL] [Abstract][Full Text] [Related]
50. Budesonide/Formoterol or Budesonide/Albuterol as Anti-Inflammatory Reliever Therapy for Asthma. Lipworth B; Kuo CR; Stewart K; Chan R J Allergy Clin Immunol Pract; 2024 Apr; 12(4):889-893. PubMed ID: 38346474 [TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Patel M; Pilcher J; Pritchard A; Perrin K; Travers J; Shaw D; Holt S; Harwood M; Black P; Weatherall M; Beasley R; Lancet Respir Med; 2013 Mar; 1(1):32-42. PubMed ID: 24321802 [TBL] [Abstract][Full Text] [Related]
53. Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study. van Schayck OC; Haughney J; Aubier M; Selroos O; Ekström T; Ostinelli J; Buhl R Respir Med; 2012 Feb; 106(2):189-96. PubMed ID: 22119455 [TBL] [Abstract][Full Text] [Related]
54. Comparing the efficacy and safety of formoterol/budesonide pMDI versus its mono-components and other LABA/ICS in patients with asthma. Mukhopadhyay A; Waked M; Gogtay J; Gaur V Respir Med; 2020; 170():106055. PubMed ID: 32843176 [TBL] [Abstract][Full Text] [Related]
55. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety. Bodzenta-Lukaszyk A; Buhl R; Balint B; Lomax M; Spooner K; Dissanayake S J Asthma; 2012 Dec; 49(10):1060-70. PubMed ID: 23102189 [TBL] [Abstract][Full Text] [Related]
56. Combination budesonide/formoterol inhaler as maintenance and reliever therapy in Māori with asthma. Pilcher J; Patel M; Smith A; Davies C; Pritchard A; Travers J; Black P; Weatherall M; Beasley R; Harwood M; Respirology; 2014 Aug; 19(6):842-51. PubMed ID: 24889937 [TBL] [Abstract][Full Text] [Related]
57. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271 [TBL] [Abstract][Full Text] [Related]
58. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice. Tamm M; Richards DH; Beghé B; Fabbri L Respir Med; 2012 Dec; 106 Suppl 1():S9-19. PubMed ID: 23273165 [TBL] [Abstract][Full Text] [Related]
59. Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol. Blais L; Beauchesne MF; Forget A Respir Med; 2009 Feb; 103(2):237-43. PubMed ID: 18930647 [TBL] [Abstract][Full Text] [Related]
60. An economic evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general practice. Goossens LM; Riemersma RA; Postma DS; van der Molen T; Rutten-van Mölken MP Adv Ther; 2009 Sep; 26(9):872-85. PubMed ID: 19768640 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]